A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine

Exclusion Criteria

• •1. Meeting criteria for other psychiatric disorders according to DSM-IV (except generalized anxiety disorder), such as schizophrenia, bipolar disorder, or mental disorders related to alcohol and drug dependence.
• •2. Current or previous history of brain organic diseases or loss of consciousness for more than 5 minutes.
• •3. Current or previous history of major physical diseases (including rheumatic immune system diseases, endocrine and metabolic diseases, nervous system diseases, etc.).
• •4. Current serious suicidal ideation or suicide attempt.
• •5. Pregnancy or lactation in women.
• •6. Color blindness (which would hinder neurocognitive testing).
• •7. Use of anticoagulants (e.g., heparin, warfarin), glucocorticoids, or treatment for thyroid diseases in the past 3 months.
• •8. Having received any neurocognitive assessment similar to this study in the past 12 months.
• •9. Positive urine drug screening results or abnormal thyroid function test.
• •10. Liver function tests showing transaminase (ALT and AST) levels 2 times above the upper limit of the normal range.
• •11. Electrocardiogram examination revealing a QTc ≥ 430 ms in males or QTc ≥ 450 ms in females.